Fracture risk remains reduced one year after discontinuation of risedronate

Overview of attention for article published in Osteoporosis International, October 2007

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

policy: 3 policy sources

Citations

dimensions_citation: 200 Dimensions

Readers on

mendeley: 96 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 3 policy documents that reference this research output.

Bisphosphonate Drugs for the Treatment of Osteoporosis in Post-Menopausal Women

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2021

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Multimorbidity: clinical assessment and management : Appendices A-Q

Cited by National Institute for Health and Care Excellence on 06 Dec 2016

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Management of osteoporosis and the prevention of fragility fractures

Cited by Scottish Intercollegiate Guidelines Network on 01 Jan 2015

The Scottish Intercollegiate Guidelines Network (SIGN) develops evidence based clinical practice guidelines for the National Health Service (NHS) in Scotland.